Adiponectin may improve osseointegration of dental implants in T2DM patients

Type 2 diabetes mellitus (T2DM) is the most common form of diabetes. Compared with the general population, a higher failure rate is seen in T2DM patients. There is also evidence that chronically high levels of plasma glycemia leads to inflammatory effect and a negative influence on bone formation and remodeling, and reduce osseointegration of implants. Recently studies reveal that adiponectin is an insulin-sensitizing adipokine, and closely associated with T2DM. Adiponectin has potent anti-inflammatory properties and has been shown to increase bone density by inhibiting osteoclast formation and promoting the formation of osteoblasts. We therefore hypothesize systemically infused or locally used adiponectin could accelerate osseointegration of dental implants in T2DM. Our hypothesis could help to create an option to improve success ratio of dental implants in T2DM by the replenishment of adiponectin in T2DM patients.